Insights

Target UTI market CirrusDx specializes in urinary tract infection testing with antimicrobial susceptibility testing for gepotidacin, signaling a strong sales hook to hospitals and clinics focusing on UTI management and antibiotic stewardship.

Integrated diagnostics Offer a combined molecular and culture-based workflow that yields actionable resistance profiles and treatment guidance, enabling selling points around faster, more precise patient care and reduced readmissions.

Women’s health focus Emphasize capabilities in women’s health testing (UTI, vaginitis, STI, wound, respiratory) to target women’s health departments, OB/GYN clinics, and accredited labs seeking comprehensive STI and vaginal infection panels.

Clinical responsiveness Highlight rapid turnaround and dedicated clinical teams with real-person support as a differentiator for hospital labs seeking reliable, customer-centric diagnostic partners.

Growth via AST Leverage recent expansion into gepotidacin susceptibility testing to align with payer and hospital procurement strategies looking to adopt new antibiotics and expand resistance testing capabilities.

Similar companies to CirrusDx, Inc.

CirrusDx, Inc. Tech Stack

CirrusDx, Inc. uses 8 technology products and services including Amazon Web Services, WordPress, Shopify, and more. Explore CirrusDx, Inc.'s tech stack below.

CirrusDx, Inc.'s Email Address Formats

CirrusDx, Inc. uses at least 1 email format:
CirrusDx, Inc. Email FormatsExamplePercentage
FLast@cirrusdx.comJDoe@cirrusdx.com
100%

Frequently Asked Questions

What is CirrusDx, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
CirrusDx, Inc.'s official website is cirrusdx.com and has social profiles on LinkedIn.

How much revenue does CirrusDx, Inc. generate?

Minus sign iconPlus sign icon
As of September 2026, CirrusDx, Inc.'s annual revenue is estimated to be $10M - $25M.

What is CirrusDx, Inc.'s NAICS code?

Minus sign iconPlus sign icon
CirrusDx, Inc.'s NAICS code is 62 - Health Care and Social Assistance.

How many employees does CirrusDx, Inc. have currently?

Minus sign iconPlus sign icon
As of September 2026, CirrusDx, Inc. has approximately 52 employees across 1 continents, including North America. Key team members include Vice President, Clinical Lab Ops: C. M., Territory Sales Manager, Northwest: S. J. and Medical Diagnostic Distributor: S. J. S. Explore CirrusDx, Inc.'s employee directory with LeadIQ.

What industry does CirrusDx, Inc. belong to?

Minus sign iconPlus sign icon
CirrusDx, Inc. operates in the Hospitals and Health Care industry.

What technology does CirrusDx, Inc. use?

Minus sign iconPlus sign icon
CirrusDx, Inc.'s tech stack includes Amazon Web Services, WordPress, Shopify, Microsoft 365, Brevo, Really Simple Discovery, Microsoft Azure and Google Analytics.

What is CirrusDx, Inc.'s email format?

Minus sign iconPlus sign icon
CirrusDx, Inc.'s email format typically follows the pattern of FLast@cirrusdx.com. Find more CirrusDx, Inc. email formats with LeadIQ.
CirrusDx, Inc. logo

CirrusDx, Inc.

Hospitals and Health CareMaryland, United States51-200 Employees

CirrusDx, Inc. is a mid-sized diagnostic laboratory based in Rockville, Maryland, operating within the hospitals and health care sector. It is a CLIA-certified facility that specializes in testing for urinary tract infections, sexually transmitted infections, vaginitis, wounds, and respiratory infections, with a particular focus on improving outcomes in women’s health. The lab emphasizes comprehensive sample workups to yield actionable diagnostic insights by examining which pathogens grow and how they behave, revealing infection complexity and resistance patterns that inform treatment decisions. Its approach integrates molecular techniques with modernized culture to provide clinicians with a broad view of infections—including the identity of pathogens, growth dynamics, interactions, and antibiotic responses. Central to CirrusDx’s offering is polyMIC, a culture-based method that identifies antibiotic susceptibilities and translates findings into personalized treatment guidance. In June 2026, CirrusDx announced the availability of antimicrobial susceptibility testing for gepotidacin (Blujepa), a recently approved oral antibiotic for uncomplicated urinary tract infections.

Section iconCompany Overview

NAICS Code
62 - Health Care and Social Assistance
Employees
51-200

Section iconFunding & Financials

  • $10M - $25M

    CirrusDx, Inc.'s revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.